BAXFENDY (baxdrostat), an aldosterone synthase inhibitor, received FDA approval as an add-on antihypertensive for treatment-resistant hypertension, demonstrating a 9.8 mmHg placebo-adjusted reduction in systolic blood pressure. The drug represents a mechanistically distinct option for patients whose blood pressure remains uncontrolled on conventional agents, though hyperkalemia risk requires careful patient selection and monitoring.
Key Points
- First-in-class aldosterone synthase inhibitor for resistant hypertension
- 9.8 mmHg placebo-adjusted systolic BP reduction at 12 weeks
- Hyperkalemia risk necessitates patient stratification and electrolyte monitoring
Longevity Analysis
Resistant hypertension accelerates vascular aging and increases risk of stroke, heart attack, and kidney disease—primary drivers of reduced healthspan. BAXFENDY addresses a treatment gap by targeting aldosterone-mediated sodium retention and vascular dysfunction through a novel mechanism, offering clinicians an additional tool when standard approaches fail. However, the hyperkalemia signal (10.2% at 2 mg dose) requires integrated monitoring of kidney function, electrolytes, and concurrent medications to prevent the very system dysregulation the drug aims to prevent. For practitioners managing patients with uncontrolled blood pressure despite multiple agents, this expands therapeutic options; for patients, it reinforces the importance of understanding individual risk factors before initiation, particularly baseline potassium levels and kidney filtration rate.
Original published by LT Wire.